News & Updates
Filter by Specialty:
Dostarlimab a miraculous cure for mismatch repair-deficient, locally advanced rectal cancer?
16 Jun 2022
Use of dostarlimab, a single-agent programmed death 1 (PD-1) monoclonal antibody, appears to have successfully cured mismatch repair-deficient, locally advanced rectal cancer, reports a recent study.
Dostarlimab a miraculous cure for mismatch repair-deficient, locally advanced rectal cancer?
16 Jun 2022Concomitant insulin may counter renoprotective effects of SGLT2is in T2D patients with CKD
16 Jun 2022
Renal composite outcomes (RCO) appear to be less favourable among type 2 diabetes (T2D) patients with chronic kidney disease (CKD) treated with insulin and sodium-glucose cotransporter 2 inhibitors (SGLT2i), a recent Japan study has found.